Gastrointestinal barriers to levodopa transport and absorption in Parkinson's disease

Levodopa is the gold standard for the symptomatic treatment of Parkinson's disease (PD). There are well documented motor and non‐motor fluctuations, however, that occur almost inevitably once levodopa is started after a variable period in people with PD. Whilst brain neurodegenerative processes...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	European journal of neurology Ročník 30; číslo 5; s. 1465 - 1480
Hlavní autoři:	Leta, Valentina, Klingelhoefer, Lisa, Longardner, Katherine, Campagnolo, Marta, Levent, Hafize Çotur, Aureli, Federico, Metta, Vinod, Bhidayasiri, Roongroj, Chung‐Faye, Guy, Falup‐Pecurariu, Cristian, Stocchi, Fabrizio, Jenner, Peter, Warnecke, Tobias, Ray Chaudhuri, K.
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	England John Wiley & Sons, Inc 01.05.2023
Témata:	Absorption Antiparkinson Agents - therapeutic use Constipation delayed gastric emptying diet Dysbacteriosis Dysphagia Fluctuations Gastric emptying Gastrointestinal Tract Helicobacter Infections - complications Helicobacter Infections - drug therapy Helicobacter pylori Humans Levodopa Levodopa - adverse effects Medical treatment medication microbiota Movement disorders Neurodegenerative diseases Parkinson Disease - complications Parkinson's disease Pathogenesis Pharmacokinetics Signs and symptoms Small intestine transport constipation microbiota Parkinson's disease absorption levodopa delayed gastric emptying dysphagia pharmacokinetics medication diet transport
ISSN:	1351-5101, 1468-1331, 1468-1331
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Buďte první, kdo okomentuje tento záznam!